• Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=25427145; PubMed=30737244).
  
• Mutation; HGNC; 1787; CDKN2A; Simple; p.Leu78Hisfs*41 (c.233_234delTC) (p.His93Profs*67, c.276_277delTC); ClinVar=VCV000977782; Zygosity=Heterozygous (PubMed=30737244).
  
• Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=25427145; PubMed=30737244).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Glu286Val (c.857A>T); ClinVar=VCV000376592; Zygosity=Heterozygous (PubMed=30737244).
  

PubMed=23833040; DOI=10.1210/jc.2013-2383
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=25427145; DOI=10.1210/jc.2014-2624
Henderson Y.C., Ahn S.-H., Ryu J., Chen Y.-Y., Williams M.D., El-Naggar A.K., Gagea M., Schweppe R.E., Haugen B.R., Lai S.Y., Clayman G.L.
Development and characterization of six new human papillary thyroid carcinoma cell lines.
J. Clin. Endocrinol. Metab. 100:E243-E252(2015)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953
Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)